PART I Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our teams deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets. Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence of new mu...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073317 | EDGAR | 113K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028328 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020607 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008284 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001193125-22-087401 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001193125-25-257357 | EDGAR | 75K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104532 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066401 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124518 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093285 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056232 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063341 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040937 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020807 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024138 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001193125-22-216780 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001193125-22-148022 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001193125-26-073304 | EDGAR | 2K words |
| 2026-01-14 | 0001193125-26-012243 | EDGAR | — |
| 2025-12-16 | 0001193125-25-320150 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314165 | EDGAR | — |
| 2025-11-20 | 0001193125-25-288770 | EDGAR | — |
| 2025-11-17 | 0001193125-25-283893 | EDGAR | — |
| 2025-10-30 | 0001193125-25-257347 | EDGAR | — |
| 2025-09-22 | 0001193125-25-209934 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104531 | EDGAR | — |
| 2025-07-21 | 0000950170-25-097069 | EDGAR | — |
88 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001861560 |
| Ticker | NUVL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nuvalent.com |
| Listed | 2021-07-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report